Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection

This study has been terminated.
(Study terminated due to an unexpected prominent effect of entecavir alone in this patient population.)
Sponsor:
Information provided by (Responsible Party):
FibroGen
ClinicalTrials.gov Identifier:
NCT01217632
First received: September 30, 2010
Last updated: August 12, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)